Previous 10 | Next 10 |
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results PR Newswire ATLANTA , April 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, an...
2023-04-20 04:57:42 ET Summary Artivion continues to trade sideways with challenges to growth looking ahead. The PROACT Xa overhang looks to be now priced in, but there's additional hurdles still to overcome. I believe AORT is overvalued and should trade at 13x forward EBITDA....
Artivion to Participate in the 22nd Annual Needham Virtual Healthcare Conference PR Newswire ATLANTA , April 10, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that i...
Artivion to Participate in the Oppenheimer 33rd Annual Healthcare Conference PR Newswire ATLANTA , March 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it wil...
Niche healthcare company Artivion (NYSE: AORT) was an outlier of a stock on Friday, rising nearly 6% higher on the back of a far better-than-expected bottom line. After reporting a surprise profit for its fourth quarter following market close on Thursday, the company's shares surged the next ...
Artivion, Inc. (AORT) Q4 2022 Earnings Conference Call February 16, 2023 04:30 PM ET Company Participants Brian Johnston - Vice President at Gilmartin Group Pat Mackin - Chairman, President & CEO Ashley Lee - EVP & CFO Conference Call Participants C...
Artivion press release ( NYSE: AORT ): Q4 Non-GAAP EPS of $0.10 beats by $0.12 . Revenue of $79.4M (flat Y/Y) misses by $0.77M . Full Year 2022 Financial Results Total revenues for 2022 were $313.8 million, reflecting an increase of 5% on a GAAP basis and 9% ...
Artivion Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire Fourth Quarter and Recent Business Highlights: Achieved revenue of $79.4 million in the fourth quarter of 2022 versus $79.4 million in the fourth quarter of 2021, flat on a GAAP ba...
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results PR Newswire ATLANTA , Feb. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aorti...
Artivion to Participate in the UBS 2022 Global Healthcare Conference PR Newswire ATLANTA , May 16, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, today announced that it wil...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 12:00:05 ET Frank Takkinen from Loop Capital Markets issued a price target of $30.00 for AORT on 2024-07-02 08:49:00. The adjusted price target was set to $30.00. At the time of the announcement, AORT was trading at $26.015. The overall price target consensus ...
Artivion Amends Agreements with Endospan PR Newswire Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million , inclusive of loan off-set, and $100 m...